MX2021002278A - Composición para erradicar helicobacter pylori. - Google Patents

Composición para erradicar helicobacter pylori.

Info

Publication number
MX2021002278A
MX2021002278A MX2021002278A MX2021002278A MX2021002278A MX 2021002278 A MX2021002278 A MX 2021002278A MX 2021002278 A MX2021002278 A MX 2021002278A MX 2021002278 A MX2021002278 A MX 2021002278A MX 2021002278 A MX2021002278 A MX 2021002278A
Authority
MX
Mexico
Prior art keywords
composition
helicobacter pylori
eradicate helicobacter
present
eradicate
Prior art date
Application number
MX2021002278A
Other languages
English (en)
Spanish (es)
Inventor
Dongkyu Kim
Ji Won Lee
Bong Tae Kim
Geun Seog Song
Shin Young Ryu
Eun Ji Kim
Kyeongmin Oh
Ahrong Kim
Eun Kyung Kim
Naree Shin
Hyun Ji Kang
Jae Min Kim
Yu Gyeong Park
Haneul Jeong
Original Assignee
Hk Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hk Inno N Corp filed Critical Hk Inno N Corp
Publication of MX2021002278A publication Critical patent/MX2021002278A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2021002278A 2018-08-29 2019-08-28 Composición para erradicar helicobacter pylori. MX2021002278A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180102250 2018-08-29
PCT/KR2019/011017 WO2020045992A1 (en) 2018-08-29 2019-08-28 Composition for eradicating helicobacter pylori

Publications (1)

Publication Number Publication Date
MX2021002278A true MX2021002278A (es) 2021-08-11

Family

ID=69643254

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002278A MX2021002278A (es) 2018-08-29 2019-08-28 Composición para erradicar helicobacter pylori.

Country Status (28)

Country Link
US (2) US20210196685A1 (cg-RX-API-DMAC10.html)
EP (1) EP3843723B1 (cg-RX-API-DMAC10.html)
JP (1) JP7189327B2 (cg-RX-API-DMAC10.html)
KR (1) KR20200026118A (cg-RX-API-DMAC10.html)
CN (1) CN112638378A (cg-RX-API-DMAC10.html)
AR (1) AR116026A1 (cg-RX-API-DMAC10.html)
AU (1) AU2019328903B2 (cg-RX-API-DMAC10.html)
CA (1) CA3107624C (cg-RX-API-DMAC10.html)
DK (1) DK3843723T3 (cg-RX-API-DMAC10.html)
EA (1) EA202190622A1 (cg-RX-API-DMAC10.html)
ES (1) ES3060114T3 (cg-RX-API-DMAC10.html)
FI (1) FI3843723T3 (cg-RX-API-DMAC10.html)
GE (2) GEP20227431B (cg-RX-API-DMAC10.html)
HR (1) HRP20260170T1 (cg-RX-API-DMAC10.html)
JO (1) JOP20190201B1 (cg-RX-API-DMAC10.html)
LT (1) LT3843723T (cg-RX-API-DMAC10.html)
MX (1) MX2021002278A (cg-RX-API-DMAC10.html)
MY (1) MY195494A (cg-RX-API-DMAC10.html)
PH (1) PH12021550385A1 (cg-RX-API-DMAC10.html)
PL (1) PL3843723T3 (cg-RX-API-DMAC10.html)
PT (1) PT3843723T (cg-RX-API-DMAC10.html)
RS (1) RS67791B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202101920WA (cg-RX-API-DMAC10.html)
SI (1) SI3843723T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202600153T1 (cg-RX-API-DMAC10.html)
UA (1) UA126993C2 (cg-RX-API-DMAC10.html)
UY (1) UY38348A (cg-RX-API-DMAC10.html)
WO (1) WO2020045992A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3132575A1 (en) * 2019-04-18 2020-10-22 Thomas Julius Borody Compositions and methods for treating, ameliorating and preventing h. pylori infections
WO2024210689A1 (ko) * 2023-04-07 2024-10-10 제이더블유중외제약 주식회사 벤즈이미다졸 유도체의 염
TW202535382A (zh) * 2023-11-29 2025-09-16 南韓商第一藥品股份有限公司 包含ｚａｓｔａｐｒａｚａｎ或其醫藥上可接受的鹽之用於幽門螺旋桿菌根除的組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753324B2 (en) * 1998-07-15 2004-06-22 Hassan Jomaa Phosphorous organic compounds and their use
WO2007072146A1 (en) 2005-12-19 2007-06-28 Pfizer Japan Inc. Chromane substituted benzimidazoles and their use as acid pump inhibitors
CN101015694A (zh) * 2006-02-07 2007-08-15 沈阳东宇药业有限公司 一种治疗幽门螺旋杆菌感染的复方口服制剂
MA41730B1 (fr) * 2015-06-08 2019-03-29 Cj Healthcare Corp Utilisation de dérivé de benzimidazole pour l'acidité nocturne
US11096948B2 (en) * 2016-01-21 2021-08-24 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection
KR101829706B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
CN108379258B (zh) * 2017-11-30 2020-02-18 中国医学科学院医药生物技术研究所 瑞香素在抗幽门螺杆菌中的应用

Also Published As

Publication number Publication date
JP2021535910A (ja) 2021-12-23
JP7189327B2 (ja) 2022-12-13
KR20200026118A (ko) 2020-03-10
US20210196685A1 (en) 2021-07-01
JOP20190201A1 (ar) 2020-02-29
UY38348A (es) 2020-03-31
EP3843723A1 (en) 2021-07-07
WO2020045992A1 (en) 2020-03-05
CA3107624A1 (en) 2020-03-05
BR112021003578A2 (pt) 2021-05-18
AR116026A1 (es) 2021-03-25
GEAP202215593A (en) 2022-07-11
EA202190622A1 (ru) 2021-06-10
LT3843723T (lt) 2026-03-25
HRP20260170T1 (hr) 2026-05-08
SI3843723T1 (sl) 2026-04-30
EP3843723A4 (en) 2022-06-29
ES3060114T3 (cg-RX-API-DMAC10.html) 2026-03-25
SMT202600153T1 (it) 2026-05-12
US20250241897A1 (en) 2025-07-31
EP3843723B1 (en) 2026-01-07
RS67791B1 (sr) 2026-03-31
JOP20190201B1 (ar) 2024-04-18
AU2019328903A1 (en) 2021-04-29
DK3843723T3 (da) 2026-02-09
PT3843723T (pt) 2026-01-27
CA3107624C (en) 2023-10-03
CN112638378A (zh) 2021-04-09
UA126993C2 (uk) 2023-03-01
GEP20227431B (en) 2022-10-25
AU2019328903B2 (en) 2023-01-05
PL3843723T3 (pl) 2026-06-08
PH12021550385A1 (en) 2021-09-20
MY195494A (en) 2023-01-26
AU2019328903A8 (en) 2021-05-27
FI3843723T3 (fi) 2026-02-12
SG11202101920WA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
PH12021550385A1 (en) Composition for eradicating helicobacter pylori
LT3781561T (lt) Metilą modifikuojančių fermentų moduliatoriai, kompozicijos ir jų naudojimas
JOP20210050A1 (ar) معدلات تعبير pnpla3
EA202191765A1 (ru) Композиция для наружного применения, включающая жизнеспособные микроорганизмы
CO2017013065A2 (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
JOP20210158A1 (ar) مُعَدِّلات التعبير الجيني عن hsd17b13
MX374111B (es) Composiciones con fragancia de liberación prolongada.
NZ758177A (en) Modulators of pcsk9 expression
CO2021008161A2 (es) Ménsula reversible
MA54386A (fr) Modulateurs de trex1
BR112018013985A2 (pt) glicosídeos de esteviol altamente solúveis
EP3953463C0 (en) STABILIZED GLYCOSIDE HYDROLASES VARIANTS
MX2017011218A (es) Composiciones edulcorantes que contienen rebaudiosidos d.
MX2021008941A (es) Moduladores gpr35.
EP3756471A4 (en) ORAL INGESTION COMPOSITION
MX2020006170A (es) Composiciones y metodos para prevenir y tratar afecciones.
EP3713586A4 (en) VIBRIO SP. ORGANISMS WITH MODIFIED LIPOPOLY SACCHARIDE
PL3813540T3 (pl) Ulepszone formulacje tuszów jadalnych zawierające węglan wapnia
CO2020003134A2 (es) Moduladores de la expresión de enac
PH12019502696A1 (en) Resorbable biodegradable medical and cosmetic composition comprising poly(1,3-trimethylene carbonate)
BR112017022340A2 (pt) 2-tiopirimidinonas
CL2019001859A1 (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta.
DK3850950T3 (da) Tyggegummisammensætninger og fremgangsmåder til fremstilling deraf
ES1192884Y (es) Dispositivo triturador de restos vegetales o de otro tipo.
EA201891794A1 (ru) Композиция для ухода за полостью рта